Wednesday, August 12, 2026
RSS

Pharmaceutical

Neurocrine Biosciences (NBIX) Faces Regulatory Scrutiny After Safety Concerns: What Investors Should Know

Neurocrine Biosciences (NBIX) faces scrutiny from regulators following safety alarms, including seven patient deaths. Here's what traders need to know.

By Sarah Chen • August 12, 2026
Pharmaceutical

Definium Therapeutics (DFTX) Phase 3 Trial Success: A Potential Game Changer for Anxiety Treatment

Definium Therapeutics' successful Phase 3 trial results could reshape anxiety treatment and boost investor sentiment.

James McAllister • Aug 12
Markets & Money

Clean Harbors Expands Footprint with $470 Million EnviroServe Acquisition

Clean Harbors is set to bolster its environmental services capabilities with the $470 million acquisition of EnviroServe.

Marcus Rivera • Aug 12
Trade with the conviction of the 1%.

Institutional-grade market intelligence delivered before the opening bell.

By subscribing, I agree to receive marketing emails and alerts. View our Privacy Policy. You may unsubscribe at any time.

More Stories
Pharmaceutical

Definium Therapeutics Soars on Trial Success: What This Means for Investors

Definium Therapeutics stock surged 20% following positive Phase 3 trial results, signaling a significant de-risking even…

Sarah Chen • Aug 12, 2026
Pharmaceutical

Regulatory Concerns Hit Neurocrine Biosciences: A Closer Look at NBIX's Safety Woes

Neurocrine Biosciences faces scrutiny after seven patient deaths linked to its drug raise regulatory alarm bells.

James McAllister • Aug 12, 2026
Markets & Money

Nasdaq's Strategic Acquisition of LeveL Markets: Implications for 24/7 Trading

Nasdaq's acquisition of LeveL Markets signals a major shift towards extended trading hours, reshaping market infrastruct…

Marcus Rivera • Aug 11, 2026
Pharmaceutical

AbCellera's ABCL635: Positive Data Fuels Market Optimism and Analyst Upgrades

AbCellera Biologics' positive Phase 2 results for ABCL635 have led to increased analyst confidence and price target adju…

Sarah Chen • Aug 11, 2026
Pharmaceutical

Replimune's FDA Approval: A New Chapter for Melanoma Treatment and Investment

Replimune secures FDA accelerated approval for TUDRIQEV, a significant milestone for melanoma treatment and investor int…

James McAllister • Aug 11, 2026
Markets & Money

H&R REIT's C$6.7 Billion Take-Private: A Game Changer for Canadian Real Estate?

H&R REIT's C$6.7 billion acquisition could reshape the Canadian commercial real estate landscape.

Marcus Rivera • Aug 11, 2026
Tech

Thoma Bravo's C$650M Acquisition of Kneat: What It Means for the Canadian Tech Landscape

Thoma Bravo's C$650M acquisition of Kneat signals a pivotal shift in the Canadian tech market amidst evolving private eq…

Sarah Chen • Aug 11, 2026
Pharmaceutical

PDS Biotech Shifts Focus to PDS0301: Implications for Investors

PDS Biotech's strategic pivot towards PDS0301 raises intriguing questions for investors.

James McAllister • Aug 11, 2026
Pharmaceutical

Amneal Pharmaceuticals Strengthens Market Position with Kashiv BioSciences Acquisition

Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, enhancing its R&D and com…

Marcus Rivera • Aug 10, 2026